Efficacy and Safety of Lipid-Lowering Drugs as Primary and Secondary Prevention of Cardiovascular Diseases in the Elderlyin the Uzbekistan

Аннотация

Management Cardiovascular diseases (CVD) are the leading cause of death worldwide. It is predicted that by 2030 .the number of deaths due to CVD will increase to 23.3 million per year [1]. The prevalence of CVD and its risk factors increases as the population's life expectancy increases [2]. According to the American Heart and Stroke Associations (American Heart Association and American Stroke Association), coronary heart disease (CHD), heart failure, stroke, hypertension, or a combination of these diseases occur in 69.1% of men and 67.9% of women aged 60-79 years and 84.7% and 85.9% over 80 years, respectively [3]. The first heart attack develops on average at the age of 65.0 years in men and 71.8 years in women, and is mainly associated with the presence of atherosclerotic lesions of the coronary bed [3]. The vast majority (about 80%) of people dying from CVD associated with atherosclerosis are people over the age of 65 [4]. In France, people aged 85 years and older account for 43% of deaths from CHD, and 49% from stroke [5].